Amazon Pharmacy to Offer $50 Weight-Loss Drugs to Medicare Users

Key Facts

In a move reflecting the growing expansion of Big Tech into the healthcare sector, Amazon's pharmacy unit has announced a new initiative targeting the weight-loss drug market. According to reports, the company will offer these medications to eligible Medicare beneficiaries for a fixed cost of $50 per month. This initiative is part of a new federal bridge program designed to expand access to highly sought-after obesity treatments for seniors and eligible individuals under the Medicare system.

This step is strategic for AMZN as it seeks to expand its healthcare market share by addressing cost and access challenges for modern treatments. Per market data, AMZN shares closed at $272.65 on August 5, 2026, with the stock seeing a day high of $282.79 and a low of $270.73. The move highlights Amazon's intent to leverage federal programs to grow its customer base within the digital pharmacy space.

Investors are watching how this expansion will impact profit margins within Amazon's health services division, with the stock at $272.65 (close of August 5, 2026). While the upcoming economic calendar shows no direct US healthcare catalysts in the next seven days, the stock's performance will remain tied to the successful execution of these federal programs and the scaling of specialized drug access.